Posttransplant cyclophosphamide beyond haploidentical transplantation.

Autor: Arcuri LJ; Academic Research Organization, Hospital Israelita Albert Einstein, Av. Albert Einstein, 627/701, São Paulo, SP, 05652-900, Brazil. leonardojavier@gmail.com.; Bone Marrow Transplantation Unit, Insituto Nacional de Cancer, Rio de Janeiro, Brazil. leonardojavier@gmail.com., Ribeiro AAF; Bone Marrow Transplantation Unit, Hospital Israelita Albert Einstein, São Paulo, Brazil., Hamerschlak N; Bone Marrow Transplantation Unit, Hospital Israelita Albert Einstein, São Paulo, Brazil., Kerbauy MN; Bone Marrow Transplantation Unit, Hospital Israelita Albert Einstein, São Paulo, Brazil.
Jazyk: angličtina
Zdroj: Annals of hematology [Ann Hematol] 2024 May; Vol. 103 (5), pp. 1483-1491. Date of Electronic Publication: 2023 Jun 01.
DOI: 10.1007/s00277-023-05300-8
Abstrakt: Posttransplant cyclophosphamide (PTCy) has practically revolutionized haploidentical (Haplo) hematopoietic cell transplantation (HCT). Comparisons between Haplo with PTCy and unrelated donor (URD) with conventional graft-versus-host disease (GVHD) prophylaxis have shown comparable overall survival with lower incidences of GVHD with Haplo/PTCy and led to the following question: is it PTCy so good that can be successfully incorporated into matched related donor (MRD) and URD HCT? In this review, we discuss other ways of doing PTCy, PTCy in peripheral blood haploidentical transplants, PTCy in the context of matched related and matched unrelated donors, PTCy with mismatched unrelated donors, and PTCy following checkpoint inhibitor treatment. PTCy is emerging as a new standard GVHD prophylaxis in haploidentical, HLA-matched, and -mismatched HCT.
(© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)
Databáze: MEDLINE
Externí odkaz: